Participant flow

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer · Source last updated 2025-12-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks). Nivolumab: nivolumab 3 mg/kg every 2 weeks Ipilimumab: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)

   id

   FG000

   title

   R/M Adenoid Cystic Carcinoma (ACC)

2. description

   Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks). Nivolumab: nivolumab 3 mg/kg every 2 weeks Ipilimumab: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)

   id

   FG001

   title

   R/M SGC of Any Histology, Except ACC (Non ACC)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         32

      2. group Id

         FG001

         num Subjects

         32

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         32

      2. group Id

         FG001

         num Subjects

         32

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice